These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pleuropulmonary disease as a side-effect of treatment with bromocriptine. Comet R; Domingo C; Such JJ; Ribera G; Sans J; Marín A Respir Med; 1998 Sep; 92(9):1172-4. PubMed ID: 9926176 [No Abstract] [Full Text] [Related]
3. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. McElvaney NG; Wilcox PG; Churg A; Fleetham JA Arch Intern Med; 1988 Oct; 148(10):2231-6. PubMed ID: 3178380 [TBL] [Abstract][Full Text] [Related]
4. [Bromocriptine in Parkinson's disease: pleuropulmonary toxicity]. Douvier JJ; Vergeret J; Taytard A; Brottier E; Domblides P; Dubos F; Freour P Ann Med Interne (Paris); 1985; 136(5):416-8. PubMed ID: 4062141 [TBL] [Abstract][Full Text] [Related]
5. Pleural disease during treatment with bromocriptine in patients previously exposed to asbestos. Hillerdal G; Lee J; Blomkvist A; Rask-Andersen A; Uddenfeldt M; Koyi H; Rasmussen E Eur Respir J; 1997 Dec; 10(12):2711-5. PubMed ID: 9493648 [TBL] [Abstract][Full Text] [Related]
6. Pergolide-induced pleuropulmonary fibrosis. Bleumink GS; van der Molen-Eijgenraam M; Strijbos JH; Sanwikarja S; van Puijenbroek EP; Stricker BH Clin Neuropharmacol; 2002; 25(5):290-3. PubMed ID: 12410064 [TBL] [Abstract][Full Text] [Related]
7. [Pleuropulmonary fibrosis and bromocriptine]. Vergeret J; Barat M; Taytard A; Bellvert P; Domblides P; Douvier JJ; Fréour P Sem Hop; 1984 Mar; 60(11):741-4. PubMed ID: 6324351 [TBL] [Abstract][Full Text] [Related]
8. [Bromocriptine and pulmonary responses]. Kinnunen E; Viljanen A Duodecim; 1989; 105(19):1614-7. PubMed ID: 2806146 [No Abstract] [Full Text] [Related]
9. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Tintner R; Manian P; Gauthier P; Jankovic J Arch Neurol; 2005 Aug; 62(8):1290-5. PubMed ID: 16087771 [TBL] [Abstract][Full Text] [Related]
10. [Bromocriptine and pleuropulmonary fibrosis]. Mouysset B; Montastruc JL; Rostin M; Caratero A; Sorbette F; Leophonte P; Rascol A Therapie; 1986; 41(1):75. PubMed ID: 3704996 [No Abstract] [Full Text] [Related]
12. Retroperitoneal fibrosis, skin and pleuropulmonary changes associated with bromocriptine therapy. Hely MA; Morris JG; Lawrence S; Jeremy R; Genge S Aust N Z J Med; 1991 Feb; 21(1):82-4. PubMed ID: 2036087 [No Abstract] [Full Text] [Related]
15. Pleural effusion and fibrosis secondary to Sansert administration. Dunn JM; Sloan H Ann Thorac Surg; 1973 Mar; 15(3):295-8. PubMed ID: 4690824 [No Abstract] [Full Text] [Related]
16. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease. Todman DH; Oliver WA; Edwards RL Clin Exp Neurol; 1990; 27():79-82. PubMed ID: 2129961 [TBL] [Abstract][Full Text] [Related]
17. Pleuropulmonary disease associated with dopamine agonist therapy. Bhatt MH; Keenan SP; Fleetham JA; Calne DB Ann Neurol; 1991 Oct; 30(4):613-6. PubMed ID: 1686385 [TBL] [Abstract][Full Text] [Related]
18. [Pleuro-pulmonary changes after bromocriptine treatment of parkinsonism]. Bøttcher J; Grøn U Ugeskr Laeger; 1981 Oct; 143(41):2648-9. PubMed ID: 7303288 [No Abstract] [Full Text] [Related]
19. [Pleuropneumopathy caused by bromocriptine in a patient with Parkinson disease. Review of the literature apropos of a new case]. Debove P; Simon F; Vaylet F; Renard JL; L'Her P Ann Med Interne (Paris); 1998 Apr; 149(3):167-71. PubMed ID: 11490541 [TBL] [Abstract][Full Text] [Related]